Role of androgen receptors in hormone-refractory prostate cancer: Molecular basics and experimental therapy approaches;Die rolle des androgenrezeptors im hormonrefraktären prostatakarzinom: Molekulare grundlagen und experimentelle therapieansätze

Urologe - Ausgabe A

Volumn 47, Issue 3, 2008, Pages 314-325

  Rinnab, L ^a   Hessenauer, A ^b   Schutz S V ^b   Schmid, E ^b   Kufer R ^a   Finter, F ^a   Hautmann, R E ^a   Spindler, K D ^b   Cronauer, M V ^b  

^a UNIVERSITY OF ULM   (Germany)

^b Institut f Allgemeinmedizin   (Germany)

Author keywords

Androgen receptor; Experimental therapeutic approaches; Growth factors; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; TYROSINE KINASE RECEPTOR;

ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER GROWTH; DNA POLYMORPHISM; EXPERIMENTAL THERAPY; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; HORMONE STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 40349089730     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-008-1637-1     Document Type: Review

References (94)

1. Hobisch A, Culig Z, Radmayr C et al. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068-3072
2. Hobisch A, Culig Z, Radmayr C et al. (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129-135
3. Koivisto P, Kononen J, Palmberg C et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319
4. Visakorpi T, Hyytinen E, Koivisto P et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406
5. Billas IM, Moras D (2005) Ligand-binding pocket of the ecdysone receptor. Vitam Horm 73: 101-129
6. McEwan IJ (2004) Sex, drugs and gene expression: signalling by members of the nuclear receptor superfamily. Essays Biochem 40: 1-10
7. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327-1335
8. Heinlein CA, Chang C (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187
9. Lu S, Jenster G, Epner DE (2000) Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14: 753-760
10. Doyu M, Sobue G, Mukai E et al. (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32: 707-710
11. Montgomery JS, Price DK, Figg WD (2001) The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146
12. Hardy DO, Scher HI, Bogenreider T et al. (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81: 4400-4405
13. Giovannucci E, Stampfer MJ, Krithivas K et al. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320-3323
14. Ingles SA, Ross RK, Yu MC et al. (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170
15. Hakimi JM, Schoenberg MP, Rondinelli RH et al. (1997) Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 3: 1599-1608
16. Freedman ML, Pearce CL, Penney KL et al. (2005) Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 76: 82-90
17. Stanford JL, Just JJ, Gibbs M et al. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194-1198
18. Correa-Cerro L, Wohr G, Haussler J et al. (1999) (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 7: 357-362
19. Newmark JR, Hardy DO, Tonb DC et al. (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89: 6319-6323
20. Lin DL, Whitney MC, Yao Z, Keller ET (2001) Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7: 1773-1781
21. Culig Z, Hobisch A, Cronauer MV et al. (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550
22. Brooke GN, Parker MG, Bevan CL (2007) Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene (Epub, doi: 10.1038/sj.onc.1210955)
23. Cronauer MV, Schulz WA, Burchardt T et al. (2003) The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 23: 1095-1102
24. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45
25. Haelens A, Tanner T, Denayer S et al. (2007) The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67: 4514-4523
26. Gregory CW, He B, Johnson RT et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319
27. Chen CD, Welsbie DS, Tran C et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39
28. Titus MA, Schell MJ, Lih FB et al. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657
29. Nakayama T, Watanabe M, Suzuki H et al. (2000) Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789-1796
30. Cronauer MV, Hittmair A, Eder IE et al. (1997) Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31: 223-233
31. Culig Z, Hobisch A, Cronauer MV et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478
32. Godoy-Tundidor S, Cavarretta IT, Fuchs D et al. (2005) Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 64: 209-216
33. Signoretti S, Montironi R, Manola J et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925
34. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285
35. McKenna NJ, O'Malley BW (2002) Minireview: nuclear receptor coactivators - an update. Endocrinology 143: 2461-2465
36. Heemers HV, Sebo TJ, Debes JD et al. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422-3430
37. Kang HY, Yeh S, Fujimoto N, Chang C (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274: 8570-8576
38. Kobayashi M, Honma T, Matsuda Y et al. (2000) Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 82: 1689-1693
39. Roose J, Clevers H (1999) TCF transcription factors: molecular switches in carcinogenesis. Biochem Biophys Acta 1424: 23-37
40. Oving IM, Clevers HC (2002) Molecular causes of colon cancer. Eur J Clin Invest 32: 448-457
41. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67
42. Wetering M van de, Sancho E, Verweij C et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250
43. Gounari F, Signoretti S, Bronson R et al. (2002) Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21: 4099-4107
44. Bierie B, Nozawa M, Renou JP et al. (2003) Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22: 3875-3887
45. Chesire DR, Isaacs WB (2003) Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 10: 537-560
46. Yang F, Li X, Sharma M et al. (2002) Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277: 11336-11344
47. Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-4713
48. Cronauer MV, Schulz WA, Ackermann R, Burchardt M (2005) Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 26: 1033-1040
49. Cronauer MV, Ince Y, Engers R et al. (2007) Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26: 1875-1884
50. Rogatsky I, Waase CL, Garabedian MJ (1998) Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem 273: 14315-14321
51. Salas TR, Kim J, Vakar-Lopez F et al. (2004) Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279: 19191-19200
52. Medunjanin S, Hermani A, De Servi B et al. (2005) Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J Biol Chem 280: 33006-33014
53. Chen S, Xu Y, Yuan X et al. (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969-15974
54. Gotz C, Kartarius S, Schetting S, Montenarh M (2005) Immunologically defined subclasses of the protein kinase CK2 beta-subunit in prostate carcinoma cell lines. Mol Cell Biochem 274: 181-187
55. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1-15
56. Hessenauer A, Montenarh M, Gotz C (2003) Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22: 1263-1270
57. Slaton JW, Unger GM, Sloper DT et al. (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2: 712-721
58. Laramas M, Pasquier D, Filhol O et al. (2007) Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 43: 928-934
59. Cronauer MV, Schulz WA, Burchardt T et al. (2004) Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23: 3541-3549
60. Peterziel H, Mink S, Schonert A et al. (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18: 6322-6329
61. Unni E, Sun S, Nan B et al. (2004) Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156-7168
62. Makridakis N, Ross RK, Pike MC et al. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57: 1020-1022
63. Nikitin AY, Matoso A, Roy-Burman P (2007) Prostate stem cells and cancer. Histol Histopathol 22: 1043-1049
64. Richardson GD, Robson CN, Lang SH et al. (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539-3545
65. Collins AT, Berry PA, Hyde C et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951
66. Cantin L, Faucher F, Couture JF et al. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 282(42): 30910-30919
67. Eder IE, Hoffmann J, Rogatsch H et al. (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9: 117-125
68. Haag P, Bektic J, Bartsch G et al. (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258
69. Haag P, Frauscher F, Gradl J et al. (2006) Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol 102: 103-113
70. Neckers L (2002) Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8: 962-966
71. Kamal A, Thao L, Sensintaffar J et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410
72. Solit DB, Zheng FF, Drobnjak M et al. (2002) 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993
73. Heath EI, Gaskins M, Pitot HC et al. (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4: 138-141
74. Agus DB, Scher HI, Higgins B et al. (1999) Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 59: 4761-4764
75. Hammarsten P, Rudolfsson SH, Henriksson R et al. (2007) Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. Prostate 67: 573-581
76. Sepp-Lorenzino L, Tjaden G, Moasser MM et al. (2001) Farnesyl: protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 4: 33-43
77. Formento P, Hannoun-Levi JM, Gerard F et al. (2005) Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 41: 1467-1473
78. Curigliano G, De Braud F, Teresa Sandri M et al. (2007) Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anticancer Drugs 18: 949-954
79. Lara PN Jr, Chee KG, Longmate J et al. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125-2131
80. Ziada A, Barqawi A, Glode LM et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337
81. Diaz LA MW, Carducci M, Pili R et al. (2007) Infliximab in patients with hormone refractory prostate cancer and bone metastases with pain. Abstractband ASCO 2007, p 268
82. Grisouard J, Medunjanin S, Hermani A et al. (2007) Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol, Epub, doi:10.1210/me.2007-0129
83. Mazor M, Kawano Y, Zhu H et al. (2004) Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23: 7882-7892
84. Wang L, Lin HK, Hu YC et al. (2004) Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279: 32444-32452
85. Liao X, Thrasher JB, Holzbeierlein J et al. (2004) Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145: 2941-2949
86. Kroncke KD, Carlberg C (2000) Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J 14: 166-173
87. Garban HJ, Marquez-Garban DC, Pietras RJ, Ignarro LJ (2005) Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci USA 102: 2632-2636
88. Cronauer MV, Stadlmann S, Klocker H et al. (1999) Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol 155: 1977-1984
89. Mizokami A, Saiga H, Matsui T et al. (1992) Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol Jpn 39: 235-243
90. Henttu P, Vihko P (1993) Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53: 1051-1058
91. Adam RM, Kim J, Lin J et al. (2002) Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143: 4599-4608
92. Culig Z, Hobisch A, Herold M et al. (1998) Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer 78: 1004-1011
93. Hobisch A, Eder IE, Putz T et al. (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645
94. Godoy-Tundidor S, Hobisch A, Pfeil K et al. (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8: 2356-2361